BXLS and Johnson & Johnson Collaborate to Fund Bleximenib Clinical Trials for AML Why is the development of new treatments for acute myeloid leukemia (AML) so critical? Despite being the…
Positive Top-Line Results for Reblozyl in Alpha-Thalassemia Study Is the treatment landscape for alpha-thalassemia about to change? Bristol Myers Squibb has announced positive top-line results from an ongoing, ex-US, Phase…
Merck Evolves Structure to Enhance Commercial Execution and Portfolio Growth In an industry where the pace of innovation and market dynamics are constantly evolving, how can pharmaceutical companies ensure they…
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences,…
AOP Health Emphasizes Collaboration and Patient-Centered Information on Rare Disease Day 2026 Why is the diagnosis and treatment of rare diseases so challenging? AOP Health, a global enterprise group with…
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Savara Inc. a clinical-stage biopharmaceutical company focused…
Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, and Neurosoft Bioelectronics, a neural data company…
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr.…
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting AstraZeneca’sCALQUENCE® in combination with venetoclax has been approved…
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric…
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration…
Element Biosciences Introduces VITARI™, Redefining What High-Throughput Sequencing Makes Possible Element Biosciences Inc. today announced VITARI, the first ever high-throughput benchtop sequencing system capable of delivering a high-quality whole genome at…